FDA Approved: CRYSVITA — Original Application (Kyowa Kirin, Inc.)

View source ↗

Summary

FDA approved CRYSVITA (burosumab) from Kyowa Kirin as the original application for the treatment of X-linked hypophosphatemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

ORIG AP for CRYSVITA (BUROSUMAB)